I continue to hold stocks in the Opportunistic and Adventurous portfolio, which I believe have the potential to outperform the market.
In my opinion, biotech is the market sector that has the biggest expanding vistas for profits and return.
It is extremely difficult, in my opinion, to select specific companies with breakthrough drugs that will get approved by the U.S. Federal Drug Administration.
One of my top five holdings is Inovio Pharmaceuticals (INO). I believe that stock may have upside if the company jump through all the FDA regulatory hoops for drug approval.
As I said, it is difficult to choose specific biotech companies where there is so much insider information not available to me.
I prefer to buy the enter sector with an investment in the ProShares Ultra Nasdaq Biotechnology ETF (BIB).
I also own a position in Skyworks Solutions (SWKS), which has delivered strong earnings in recent quarters.
In addition, I am also positive about the prospects for Gentherm (THRM) and Ambarella (AMBA). Both have delivered steady long-term growth that I like to see.
DISCLAIMER: The investments discussed are held in client accounts as of October 31, 2014. These investments may or may not be currently held in client accounts. The reader should not assume that any investments identified were or will be profitable or that any investment recommendations or investment decisions we make in the future will be profitable. Past performance is no guarantee of future results.